Antonia Morga

Addlestone, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Incorporating estimands into meta-analyses of clinical trials.

Incorporating estimands into meta-analyses of clinical trials.

Journal: Research synthesis methods

Published: July 30, 2026

Patient-reported outcome data from a randomized phase II study (STARLIGHT) of fezolinetant in women in Japan with vasomotor symptoms associated with menopause.

Patient-reported outcome data from a randomized phase II study (STARLIGHT) of fezolinetant in women in Japan with vasomotor symptoms associated with menopause.

Journal: Climacteric : the journal of the International Menopause Society

Published: May 20, 2026

Fezolinetant treatment for hot flashes associated with menopause: A plain language summary of the DAYLIGHT study.

Fezolinetant treatment for hot flashes associated with menopause: A plain language summary of the DAYLIGHT study.

Journal: Women's health (London, England)

Published: April 03, 2026

Estimated impact of fezolinetant versus placebo on work productivity and indirect costs among women experiencing vasomotor symptoms associated with menopause.

Estimated impact of fezolinetant versus placebo on work productivity and indirect costs among women experiencing vasomotor symptoms associated with menopause.

Journal: Menopause (New York, N.Y.)

Published: July 31, 2025

Fezolinetant compared with elinzanetant for the treatment of vasomotor symptoms associated with menopause: A matching-adjusted indirect comparison.

Fezolinetant compared with elinzanetant for the treatment of vasomotor symptoms associated with menopause: A matching-adjusted indirect comparison.

Journal: Maturitas

Published: July 30, 2025

PERCEIVE: A retrospective, qualitative interview-based study of the impact of vasomotor symptoms associated with menopause on the lives of individuals who are not suitable candidates for hormone therapy.

PERCEIVE: A retrospective, qualitative interview-based study of the impact of vasomotor symptoms associated with menopause on the lives of individuals who are not suitable candidates for hormone therapy.

Journal: Maturitas

Published: June 10, 2025

Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy.

Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy.

Journal: Current medical research and opinion

Published: March 05, 2025

The Burden of Illness of Treatment-Induced Vasomotor Symptoms in Individuals with Breast Cancer: A Systematic Literature Review.

The Burden of Illness of Treatment-Induced Vasomotor Symptoms in Individuals with Breast Cancer: A Systematic Literature Review.

Journal: Journal of clinical medicine

Published: December 24, 2024

Impact of Dry Age-Related Macular Degeneration on Daily Activities and Quality of Life: Interview Findings From Patients and Caregivers Relative to a General Population.

Impact of Dry Age-Related Macular Degeneration on Daily Activities and Quality of Life: Interview Findings From Patients and Caregivers Relative to a General Population.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: September 13, 2024

Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.

Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.

Journal: Maturitas

Published: July 19, 2024

Correction to: Psychometric Evaluation of the MENQOL Instrument in Women Experiencing Vasomotor Symptoms Associated with Menopause.

Correction to: Psychometric Evaluation of the MENQOL Instrument in Women Experiencing Vasomotor Symptoms Associated with Menopause.

Journal: Advances in therapy

Published: April 23, 2024

Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).

Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).

Journal: Menopause (New York, N.Y.)

Published: April 16, 2024

Showing 1-12 of 24

Last Updated: 09/26/2026